Literature DB >> 23441756

Effect of the TRPV1 antagonist SB-705498 on the nasal parasympathetic reflex response in the ovalbumin sensitized guinea pig.

Kumar Changani1, Sarah Hotee, Simon Campbell, Kashmira Pindoria, Laura Dinnewell, Paula Saklatvala, Sally-Anne Thompson, Diane Coe, Keith Biggadike, Giovanni Vitulli, Marion Lines, Albert Busza, Jane Denyer.   

Abstract

BACKGROUND AND
PURPOSE: Nasal sensory nerves play an important role in symptoms associated with rhinitis triggered by environmental stimuli. Here, we propose that TRPV1 is pivotal in nasal sensory nerve activation and assess the potential of SB-705498 as an intranasal therapy for rhinitis. EXPERIMENTAL APPROACH: The inhibitory effect of SB-705498 on capsaicin-induced currents in guinea pig trigeminal ganglion cells innervating nasal mucosa was investigated using patch clamp electrophysiology. A guinea pig model of rhinitis was developed using intranasal challenge of capsaicin and hypertonic saline to elicit nasal secretory parasympathetic reflex responses, quantified using MRI. The inhibitory effect of SB-705498, duration of action and potency comparing oral versus intranasal route of administration were examined. KEY
RESULTS: SB-705498 concentration-dependently inhibited capsaicin-induced currents in isolated trigeminal ganglion cells (pIC50 7.2). In vivo, capsaicin ipsilateral nasal challenge (0.03-1 mM) elicited concentration-dependent increases in contralateral intranasal fluid secretion. Ten per cent hypertonic saline initiated a similar response. Atropine inhibited responses to either challenge. SB-705498 inhibited capsaicin-induced responses by ∼50% at 10 mg·kg⁻¹ (oral), non-micronized 10 mg·mL⁻¹ or 1 mg·mL⁻¹ micronized SB-705498 (intranasal) suspension. Ten milligram per millilitre intranasal SB-705498, dosed 24 h prior to capsaicin challenge produced a 52% reduction in secretory response. SB-705498 (10 mg·mL⁻¹, intranasal) inhibited 10% hypertonic saline responses by 70%. CONCLUSIONS AND IMPLICATIONS: The paper reports the development of a guinea pig model of rhinitis. SB-705498 inhibits capsaicin-induced trigeminal currents and capsaicin-induced contralateral nasal secretions via oral and intranasal routes; efficacy was optimized using particle-reduced SB-705498. We propose that TRPV1 is pivotal in initiating symptoms of rhinitis.
© 2013 GlaxoSmithKline. British Journal of Pharmacology © 2013 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23441756      PMCID: PMC3682706          DOI: 10.1111/bph.12145

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Epithelial shedding is associated with nasal reactions to cold, dry air.

Authors:  Alvaro A Cruz; Robert M Naclerio; David Proud; Alkis Togias
Journal:  J Allergy Clin Immunol       Date:  2006-05-02       Impact factor: 10.793

Review 2.  Clinically useful vanilloid receptor TRPV1 antagonists: just around the corner (or too early to tell)?

Authors:  Giovanni Appendino; Arpad Szallasi
Journal:  Prog Med Chem       Date:  2006

Review 3.  Trigeminally-mediated health effects of air pollutants: sources of inter-individual variability.

Authors:  D Shusterman
Journal:  Hum Exp Toxicol       Date:  2007-03       Impact factor: 2.903

4.  Changes in osmolality sensitize the response to capsaicin in trigeminal sensory neurons.

Authors:  Lieju Liu; Lei Chen; Wolfgang Liedtke; S A Simon
Journal:  J Neurophysiol       Date:  2007-03       Impact factor: 2.714

Review 5.  Mechanisms and mediators of nasal symptoms in non-allergic rhinitis.

Authors:  R J Salib; P G Harries; S B Nair; P H Howarth
Journal:  Clin Exp Allergy       Date:  2008-01-14       Impact factor: 5.018

6.  Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.

Authors:  Martin J Gunthorpe; Sara Luis Hannan; Darren Smart; Jeffrey C Jerman; Sandra Arpino; Graham D Smith; Stephen Brough; Jim Wright; Julie Egerton; Sarah C Lappin; Vicky A Holland; Kim Winborn; Mervyn Thompson; Harshad K Rami; Andrew Randall; John B Davis
Journal:  J Pharmacol Exp Ther       Date:  2007-03-28       Impact factor: 4.030

7.  The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation.

Authors:  Narender R Gavva; Anthony W Bannon; Sekhar Surapaneni; David N Hovland; Sonya G Lehto; Anu Gore; Todd Juan; Hong Deng; Bora Han; Lana Klionsky; Rongzhen Kuang; April Le; Rami Tamir; Jue Wang; Brad Youngblood; Dawn Zhu; Mark H Norman; Ella Magal; James J S Treanor; Jean-Claude Louis
Journal:  J Neurosci       Date:  2007-03-28       Impact factor: 6.167

8.  Neuronal markers in allergic rhinitis: expression and correlation with sensory testing.

Authors:  Stephen O'Hanlon; Paul Facer; Karen D Simpson; Guri Sandhu; Hesham A Saleh; Praveen Anand
Journal:  Laryngoscope       Date:  2007-09       Impact factor: 3.325

Review 9.  Neural aspects of allergic rhinitis.

Authors:  Dennis Kim; James N Baraniuk
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2007-08       Impact factor: 2.064

Review 10.  The emerging role of TRPV1 in diabetes and obesity.

Authors:  Anish Suri; Arpad Szallasi
Journal:  Trends Pharmacol Sci       Date:  2007-12-04       Impact factor: 14.819

View more
  6 in total

1.  The pharmacology of TRP channels.

Authors:  Peter Holzer; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

2.  Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels.

Authors:  Luciano De Petrocellis; Aniello Schiano Moriello; Gabriele Fontana; Alessandro Sacchetti; Daniele Passarella; Giovanni Appendino; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

3.  Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1 antagonist.

Authors:  Carlijn Holland; Cornelis van Drunen; Jane Denyer; Kevin Smart; Christine Segboer; Ingrid Terreehorst; Amy Newlands; Misba Beerahee; Wytske Fokkens; Daphne C Tsitoura
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

4.  A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers.

Authors:  Rachel A Gibson; Jon Robertson; Harshna Mistry; Stewart McCallum; Disala Fernando; Melody Wyres; Gil Yosipovitch
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

Review 5.  TRPV1 and TRPM8 in Treatment of Chronic Cough.

Authors:  Eva Millqvist
Journal:  Pharmaceuticals (Basel)       Date:  2016-07-28

6.  The role of TRPV1 in the CD4+ T cell-mediated inflammatory response of allergic rhinitis.

Authors:  Ramachandran Samivel; Dae Woo Kim; Hye Ran Son; Yun-Hee Rhee; Eun Hee Kim; Ji Hye Kim; Jun-Sang Bae; Young-Jun Chung; Phil-Sang Chung; Eyal Raz; Ji-Hun Mo
Journal:  Oncotarget       Date:  2016-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.